Sterility Testing Market Overview
The global Sterility Testing Market size was estimated at USD 1,484.0 million in 2025 and is projected to reach USD 3,743.2 million by 2033, growing at a CAGR of 12.22% during the forecast period (2026-2033).
Sterility testing is a GMP (Good Manufacturing Process) microbiology testing requirement to ensure that sterile products are free of viable microorganisms before release and patient administration.
Sterility Testing Market Summary
| Metrics | Details |
| Market CAGR | 12.22% |
| Segments Covered | By Product Type, By Test Type, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights about the Market Request Free Sample
Sterility Testing Market Dynamics and Trends
The major factors contributing to the growth of the global sterility testing market are the increasing R&D, and the increasing number of drug approvals is expected to drive the market growth.
The increasing number of drug approvals is expected to drive the market growth in the forecast period
The development or validation of product-specific methods and reliable sterility testing are critical steps in drug development. Sterility testing is required to ensure no viable contaminating microorganisms in a product. This testing is done in an isolator or cleanroom environment using direct inoculation or membrane filtration methods. Pharmaceutical articles must be sterile tested during the sterilization validation process and routine release testing. USP requirements use sterility testing as an official test to determine the suitability of a lot.
The problems associated with sterility testing is expected to hamper the market growth
In addition to the significant limitation of testing sterilized products, there is also the uncertainty associated with sterility testing execution. Contamination of the test by non–product-related microorganisms is one of the issues with sterility testing. The USP describes a typical contamination rate for sterility testing of 0.1 percent or 1 per 1,000 samples. This level is likely to rise as test article size, complexity, and manipulation increase. Thus, even if one attempted to test the fully sterilized product with the massive sample size required to verify a typical SAL of 106, the test method would almost certainly fall short of the required precision. In addition to the significant limitation of testing sterilized products, there is also the uncertainty associated with sterility testing execution.
Based on application, the pharmaceutical and biological manufacturing segment is expected to drive the market growth
Sterility testing is performed at all pharmaceutical and biological product manufacturing levels to reduce the risk of product contamination. The rapid growth of the pharmaceutical and biological industries will significantly increase the overall use of sterility testing, resulting in high demand for sterility testing products and solutions. Sterility testing is performed in the manufacturing process of any pharmaceutical or biological product for raw materials, finished product, and even before the final product is released to ensure the absence of microorganisms as per the mandated regulations of the regulatory authority or institutions, and as the demand for pharmaceutical and medical products for various health conditions increases, so does the frequency of sterility testing in the industries. Furthermore, rising investment in research and development and increasing regulatory approvals for drugs and other biologics are propelling new drugs and products, which is expected to fuel the market in the coming years.
Global Sterility Testing Market Geographical Share
North America region is expected to hold the largest market share in the global sterility testing market
The increased research and innovation in the biotechnology and pharmaceutical industries in the regions increased investment in research and development activities in the life sciences and medical technology, and favorable government initiatives are expected to drive the market growth.
Furthermore, high-end research activities in academics and research institutes will drive the growth of the country's sterility testing market over the forecast period.
Key Developments
March 2026: Nelson Labs launched RapidCert, an advanced rapid sterility testing service delivering results in as little as 6 days for medical devices and pharmaceuticals, significantly accelerating product release timelines compared to traditional 14-day methods while maintaining compliance with FDA and USP standards.
January 2026: Charles River Laboratories expanded its sterility testing kits and reagents portfolio with next-gen membrane filtration reagents, capturing over 50% market share through improved sensitivity for large-volume injectables.
November 2025: bioMérieux SA introduced a real-time rapid sterility assay system using automated fluorescence detection, reducing testing time to 48 hours for critical sterile products.
Sterility Testing Market Companies and Competitive Landscape
The global sterility testing market is highly competitive with mergers, collaborations, and product launches. Some of the major key players in the market are BioMérieux, Charles River Laboratories, Inc., Merck KGaA, Sartorius AG, SGS S.A., Sotera Health LLC, Thermo Fisher Scientific, Alcami Corporation, Redberry, Lucideon
Redberry
Overview: Redberry company creates new platforms to avoid the culture phase of microorganisms in industrial microbiology and thus provide immediate results at previously unheard-of costs, performance, and ease-of-use. It was founded in 2017.
Product Portfolio:Red One, a fully automated rapid microbial detection. Red One detects viable active microorganisms (bacteria, yeasts, and moulds) and eukaryotic cells. It can count samples with concentrations ranging from 10 to 5 10e5 microorganisms per cap (linear range).
